Xoma Royalty Corporation (XOMA)

$24.39 +0.17 (0.72%)
Market Cap 296.30M
Revenue (ttm) 28.49M
Net Income (ttm) -13.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,092.86
Profit Margin -48.51%
Debt to Equity Ratio 1.34
Volume 25,000
Avg Vol 33,218
Day's Range N/A - N/A
Shares Out 11.97M
Stochastic %K 7%
Beta 0.89
Analysts Strong Sell
Price Target $64.67

Latest News on XOMA

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025, 8:01 AM EDT - 8 days ago

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 7:30 AM EDT - 4 weeks ago

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

Apr 14, 2025, 7:30 AM EDT - 7 weeks ago

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

Apr 8, 2025, 7:15 AM EDT - 2 months ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

TAK

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

Apr 8, 2025, 12:24 AM EDT - 2 months ago

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

Apr 2, 2025, 7:30 AM EDT - 2 months ago

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

XOMA Royalty Declares Quarterly Preferred Stock Dividends

Mar 20, 2025, 7:30 AM EDT - 2 months ago

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Mar 17, 2025, 4:30 PM EDT - 2 months ago

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Feb 25, 2025, 7:00 AM EST - 3 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

XOMA Royalty to Present at Investor Conferences in March

Feb 24, 2025, 4:05 PM EST - 3 months ago

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 4 months ago

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Nov 7, 2024, 7:30 AM EST - 7 months ago

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Oct 22, 2024, 8:00 AM EDT - 8 months ago

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Oct 22, 2024, 8:00 AM EDT - 8 months ago

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

TWST

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15, 2024, 10:31 AM EDT - 8 months ago

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 8 months ago

I Am Banking On The Silver Tsunami With Big Dividends

HROW THQ

XOMA Stock Dips Amidst Biotech Sector Decline

Oct 3, 2024, 3:53 PM EDT - 8 months ago

XOMA Stock Dips Amidst Biotech Sector Decline

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

Sep 23, 2024, 6:30 AM EDT - 9 months ago

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty to Present at Upcoming Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 9 months ago

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Aug 13, 2024, 7:30 AM EDT - 10 months ago

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

My 2 Top Royalty Income Picks, Yields Up To 9.5%

Jul 19, 2024, 8:30 AM EDT - 11 months ago

My 2 Top Royalty Income Picks, Yields Up To 9.5%

KRP

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29, 2024, 2:31 AM EDT - 1 year ago

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

XOMA Declares Quarterly Preferred Stock Dividends

Jun 20, 2024, 7:30 AM EDT - 1 year ago

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

Jun 12, 2024, 7:30 AM EDT - 1 year ago

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

Jun 3, 2024, 7:45 PM EDT - 1 year ago

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

May 14, 2024, 7:30 AM EDT - 1 year ago

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

May 9, 2024, 7:30 AM EDT - 1 year ago

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Apr 25, 2024, 7:30 AM EDT - 1 year ago

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB PGEN

XOMA Corporation Announces Closing of Tender Offer

Apr 3, 2024, 9:00 AM EDT - 1 year ago

XOMA Corporation Announces Closing of Tender Offer

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Mar 19, 2024, 4:05 PM EDT - 1 year ago

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Mar 13, 2024, 11:49 AM EDT - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Mar 8, 2024, 7:30 AM EST - 1 year ago

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

XOMA to Present at Upcoming Investor Conferences in March

Feb 28, 2024, 7:30 AM EST - 1 year ago

XOMA to Present at Upcoming Investor Conferences in March

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Feb 19, 2024, 11:03 AM EST - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Feb 16, 2024, 8:00 AM EST - 1 year ago

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Jan 18, 2024, 8:30 AM EST - 1 year ago

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

Jan 11, 2024, 4:05 PM EST - 1 year ago

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

Jan 8, 2024, 7:30 AM EST - 1 year ago

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Announces Stock Repurchase Program of up to $50 Million

Jan 2, 2024, 7:30 AM EST - 1 year ago

XOMA Announces Stock Repurchase Program of up to $50 Million

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Dec 19, 2023, 7:30 AM EST - 1 year ago

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

I'm Buying Preferred Stocks Hand Over Fist

Dec 15, 2023, 8:30 AM EST - 1 year ago

I'm Buying Preferred Stocks Hand Over Fist

TDS

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Nov 7, 2023, 7:30 AM EST - 1 year ago

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Oct 31, 2023, 7:30 AM EDT - 1 year ago

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:30 AM EDT - 1 year ago

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Aug 8, 2023, 7:30 AM EDT - 1 year ago

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

XOMA Added to the Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 6:14 PM EDT - 2 years ago

XOMA Added to the Russell 2000® and Russell 3000® Indexes

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

Jun 22, 2023, 7:30 AM EDT - 2 years ago

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

Jun 22, 2023, 7:30 AM EDT - 2 years ago

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

May 9, 2023, 7:30 AM EDT - 2 years ago

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy